Skip to main content
. 2020 Jun 4;5(11):e137393. doi: 10.1172/jci.insight.137393

Figure 6. PAR2 agonists effectuate facial grimacing via PAR2+ sensory neurons.

Figure 6

Mice were injected with PAR2 agonists and grimacing was subsequently scored 1, 3, 5, 24, and 48 hours after hind paw injection. Baseline (BL) measures were obtained before administering 2AT, 48/80, or NE. When compared with F2rl1floxPirt+/+ mice, F2rl1floxPirtCre mice show decreased facial grimacing in response to 2AT (30 pmol) (A), 48/80 (6.5 nmol) (B), and NE (10 units) (C). Effect size is determined by calculating the cumulative difference between the value for each time point and the baseline value. *P < 0.05 compared with F2rl1floxPirt+/+ or F2rl1floxPirtCre groups. #P < 0.05 compared with baseline measures. n = 4 for F2rl1floxPirt+/+ and F2rl1floxPirtCre groups treated with 2AT and 48/80, n = 7 for F2rl1floxPirt+/+ and F2rl1floxPirtCre groups treated with NE. Data are expressed as mean ± SEM. Two-way ANOVA used for grimace score, with Holm-Šidák and Dunnett’s multiple comparisons: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; ##P < 0.01, ###P < 0.001, and ####P < 0.0001. Unpaired t test used for effect size: **P < 0.01, and ****P < 0.0001. Asterisks denote significant differences between genotypes. Pound signs denote significant differences versus BL as a function of time.